Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,370.24 47.75 −3.37%
Market cap
$1.28T
P/E
44.5×
Fwd P/E
41.5×
Dividend yield
0.49%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100

Eli Lilly and Company (LLY) Book value per share

Alert me on Book value per share

Eli Lilly and Company's book value per share at the end of fiscal 2025 was 29.6×, up 86.6% from 15.8× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 45.2×. Over the past ten years it has ranged from 2.9× (fiscal 2019) to 29.6× (fiscal 2025) — the current reading is the highest in ten years. Eli Lilly and Company ranks 2nd of 21 Drug Manufacturers General companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 29.6× 86.61%
FY2024 15.8× 31.31%
FY2023 12.1× 0.99%
FY2022 11.9× 18.38%
FY2021 10.1× 57.27%
FY2020 6.4× 121.39%
FY2019 2.9× (72.69%)
FY2018 10.6× (4.29%)
FY2017 11.1× (16.64%)
FY2016 13.3× (3.17%)

Quarterly newest first

Period Book value per share Change
Sep 2026 45.2× 18.93%
Jun 2026 38.0× 8.85%
Mar 2026 34.9× 17.94%
Dec 2025 29.6× 11.20%
43 more quarters

Against its own ten years

Low 2.9× High 29.6×
Ten-year median 11.9×
Current reading's percentile 100

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on LLY